Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP et al (2017) Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 376(10):917–927

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P et al (2021) Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia 35(2):440–453

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C et al (2016) Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J ClinOncol Off J Am SocClinOncol 34(20):2333–2340

Article  CAS  Google Scholar 

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ et al (2019) Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med 381(24):2315–2326

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C et al (2021) Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 138(21):2042–2050

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TML (2016) Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J ClinOncol Off J Am SocClinOncol 34(24):2851–2857

Article  CAS  Google Scholar 

Caldemeyer L, Dugan M, Edwards J, Akard L (2016) Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. CurrHematolMalig Rep 11(2):71–79

Google Scholar 

Gupta N, Mahapatra M, Seth T, Tyagi S, Sazawal S, Saxena R (2021) Social and Financial Barriers to Optimum TKI Treatment in Patients with Chronic Myeloid Leukemia-A Knowledge-Attitudes-Practices Study from India. Mediterr J Hematol Infect Dis 13(1):e2021004

Article  PubMed  PubMed Central  Google Scholar 

Abruzzese E, Mauro M, Apperley J, Chelysheva E (2020) Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. TherAdvHematol 31(11):2040620720966120

Google Scholar 

Sabnis HS, Keenum C, Lewis RW, Patterson B, Bergsagel J, Effinger KE et al (2019) Growth disturbances in children and adolescents receiving long-term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia. Br J Haematol 185(4):795–799

Article  PubMed  Google Scholar 

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966–984

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pavlovsky C, Abello Polo V, Pagnano K, Varela AI, Agudelo C, Bianchini M et al (2021) Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel. Blood Adv 5(23):4855–4863

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hughes TP, Ross DM (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood 128(1):17–23

Article  CAS  PubMed  Google Scholar 

Malhotra H, Radich J, Garcia-Gonzalez P (2019) Meeting the needs of CML patients in resource-poor countries. Hematol Am SocHematolEduc Program 2019(1):433–442

Google Scholar 

Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966–984. https://doi.org/10.1038/s41375-020-0776-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goni D, Jain A, Singh C, Jindal N, Nampoothiri R, Jandial A et al (2023) Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study. Indian J Med Res 157(1):87–91

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bansal S, Prabhash K, Parikh P (2013) Chronic myeloid leukemia data from India. Indian J Med PaediatrOncolOff J Indian Soc Med PaediatrOncol 34(3):154–158

Article  Google Scholar 

Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A et al (2017) Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J ClinOncol Off J Am SocClinOncol 35(3):298–305

Article  Google Scholar 

Mughal TI, Schrieber A (2010) Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biol Targets Ther 4:315–323

Article  CAS  Google Scholar 

Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113(22):5401–5411

Article  CAS  PubMed  Google Scholar 

Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ et al (2019) Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol 94(1):46–54

Article  CAS  PubMed  Google Scholar 

Ross DM, Pagani IS, Shanmuganathan N, Seymour JF, Mills AK, Filshie RJ et al (2017) Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML). Blood 8(130):1597

Google Scholar 

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19(6):747–757

Article  CAS  PubMed  Google Scholar 

Rousselot P, Loiseau C, Delord M, Cayuela JM, Spentchian M (2020) Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv 4(13):3034–3040

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inzoli E, Aroldi A, Piazza R, Gambacorti-Passerini C (2022) Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success. Am J Hematol 97(8):1075–1085

Article  CAS  PubMed  PubMed Central  Google Scholar 

Branford S, Yeung DT, Prime JA, Choi SY, Bang Hee J, Park JE et al (2012) BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood 119(18):4264–71

Article  CAS  PubMed  Google Scholar 

Diral E, Mori S, Antolini L, Abruzzese E, Le Coutre P, Martino B et al (2020) Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. Blood 136(19):2237–2240

Article  CAS  PubMed  Google Scholar 

Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11(11):1029–1035

Article  CAS  PubMed  Google Scholar 

Ross DM, Masszi T, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E et al (2018) Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res ClinOncol 144(5):945–954

Article  CAS  Google Scholar 

Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E et al (2015) Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol 90(10):910–914

Article  CAS  PubMed  Google Scholar 

Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Byrne J et al (2019) Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). Blood 134(Supplement_1):26–26

Article  Google Scholar 

Breccia M, Abruzzese E, Annunziata M, Luciano L, Sica S (2021) Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia. Front Oncol 10(11):631570

Article  Google Scholar 

Shanmuganathan N, Braley JA, Yong ASM, Hiwase DK, Yeung DT, Ross DM et al (2019) Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood 134(1):85–89

Article  CAS  PubMed  Google Scholar